- Home
- FMC vs PSNL Comparison
FMC vs PSNL Comparison
Compare FMC & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FMC | PSNL |
|---|---|---|
| Founded | 1910 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FMC | PSNL |
|---|---|---|
| Price | $8.30 | $16.00 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 17 | 5 |
| Target Price | $13.26 | ★ $15.17 |
| AVG Volume (30 Days) | ★ 4.1M | 1.9M |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | ★ 3.59% | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,727,800,000.00 | $69,648,000.00 |
| Revenue This Year | $3.22 | $21.10 |
| Revenue Next Year | $4.11 | $30.66 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.42 | $4.96 |
| 52 Week High | $31.30 | $18.89 |
Technical Indicators
Market Signals| Indicator | FMC | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 30.46 | 47.55 |
| Support Level | N/A | $15.96 |
| Resistance Level | $12.37 | $16.39 |
| Average True Range (ATR) | 0.44 | 0.38 |
| MACD | -0.07 | -0.09 |
| Stochastic Oscillator | 3.33 | 30.73 |
Price Performance
Historical ComparisonAbout FMC FMC Corporation
FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.